Purine Antimetabolite

Leukemia, Hairy Cell

Lymphoma, Non-Hodgkin

Multiple Sclerosis

Leukemia, Lymphocytic, Chronic, B-Cell

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">MAVENCLAD contains the nucleoside metabolic inhibitor cladribine, which is a white or almost white, non-hydroscopic, crystalline powder with the molecular formula C<span class="Sub">10</span>H<span class="Sub">12</span>ClN<span class="Sub">5</span>O<span class="Sub">3</span> and molecular weight 285.69. It differs in structure from the naturally occurring nucleoside, deoxyadenosine, by the substitution of chlorine for hydrogen in the 2-position of the purine ring. The chemical name of cladribine is 2-chloro-2'-deoxy-adenosine.</p><p>The structural formula isshown below:</p><div class="Figure"><img alt="Chemical Structure" src="mavenclad-01.jpg"/></div><p>Cladribine is stable at slightly basic and at neutral pH. The main degradation pathway is hydrolysis and at acidic pH significant decomposition occurs with time. The ionization behavior of the molecule over the pH range 0 to 12 is characterized by a single pKa of approximately 1.21.</p><p>MAVENCLAD is provided as 10 mg tablets for oral use. Each MAVENCLAD 10 mg tablet contains cladribine as an active ingredient and hydroxypropyl betadex, magnesium stearate, and sorbitol as inactive ingredients.</p></section>

Mavenclad

cladribine 10 MG Oral Tablet

cladribine 10 MG Oral Tablet [Mavenclad]

cladribine

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Medication Guide 

Submit MSL Request 

Pharmacy List 

Reimbursement Information

Coverage Authorization Request 

Coverage Authorization Appeals 

Mavenclad Service Request Form 

Enroll in Patient Savings Program 

Prescribing Mavenclad 

MS LifeLines Pro: HCP Portal 

About Mavenclad 

Side Effects 

Taking Mavenclad 

MS Lifelines Patient Support 

Mavenclad Start Guide 

Patient Stories 

Patient Resources 

Instructions For Use: Multiple Sclerosis 

Doctor Discussion Guide 